Navigation Links
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Date:5/16/2012

ajority of the cases are considered allergic asthma, for which there is no known cure.  Acute and severe episodes of the disease make up approximately two million Emergency Room visits each year, accounting for 25% of all visits.

R343, Inhaled SYK Inhibitor
In patients with allergic asthma, allergens, such as pollen, trigger the production of immunoglobulin E (IgE) antibodies, which then bind to mast cells (the body's defense system gatekeepers in the lung) and spark a cascade of intracellular signals to mount an immune response resulting in swelling and inflammation of the airways. SYK is a protein tyrosine kinase that plays a pivotal role in IgE receptor signaling in mast cells. Rigel's R343 is designed to bind to the SYK in mast cells and to interrupt the signal from the IgE receptors. R343's ability to inhibit SYK potentially prevents or stops the immune response to the allergen and may be effective in the short and long-term control of allergic asthma.

Rigel expects to initiate a multi-center, multiple-dose, and placebo-controlled study with R343 in approximately 270 asthma patients this summer.

To view Rigel's R343 Asthma Animation, please go to: http://www.rigel.com/rigel/aa.

R256, Inhaled IL13 Signaling /JAK Inhibitor
In patients with severe or chronic asthma, the cells lining the walls of the respiratory airways and lungs experience persistent inflammation and cellular remodeling resulting in scarring (pulmonary fibrosis) if left untreated.   Inhibition of JAK along the IL13 and IL4 signaling pathways, at the primary cellular level of the airways, may reduce or stop the inflammatory cascade associated with bronchospasms, mucus overproduction, cell wall thickening and other symptoms of chronic lung obstruction.  Rigel has conducted preclinical studies with R256 in a variety of models and expects to initiate preclinical development leading to an I
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  Luminex Corporation (NASDAQ: ... the Morgan Stanley Global Healthcare Conference to be held ... Hotel in New York City . ... a.m. Eastern time on Friday, September 18, 2015.  The ... Luminex Corporation,s website at http://www.luminexcorp.com . Simply log on ...
(Date:9/4/2015)... , September 4, 2015 ... by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by ... and by Product - Global Forecast to 2020", published ... reach USD 2.5 Billion by 2020, growing at a ... to 2020. Browse 139 Tables and ...
(Date:9/4/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Rodman & Renshaw 17 th Annual Global Investment ... New York City .  Dr. Michael Berelowitz ... on September 9, 2015. Presentation Details: ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... UPI ), a medical device company ... to treat voiding dysfunctions, today announced that Noridian ... both regional Medicare carriers, now cover percutaneous, posterior ... Neuromodulation System for the treatment of the symptoms ...
... was voted the most powerful person in healthcare by readers ... business news magazine. It,s the second consecutive year Obama topped ... in Healthcare. "The passage of national healthcare reform ... Modern Healthcare Editor David Burda. "The Patient Protection ...
Cached Medicine Technology:Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 2Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 3Obama Named the Most Powerful Person in Healthcare for Second Consecutive Year 2
(Date:9/4/2015)... San Diego, California (PRWEB) , ... September 04, 2015 , ... ... affiliates on behalf of Tanya De La Paz. , Schmidt National Law Group, ... for the Northern District of California against Bayer Corp., Bayer Essure, Inc., and other ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar ... (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply ... constantly evolving in the consumer goods industry, it can be difficult for companies ...
(Date:9/4/2015)... Maui HI (PRWEB) , ... September 04, 2015 , ... ... the best ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” says ... and his team at Four Seasons Resort Maui, the island’s only Forbes Five Star ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat ... at the 2015 symposium are doctors and researchers at the top of their ...
(Date:9/4/2015)... DC (PRWEB) , ... September 04, 2015 , ... ... they all pale in comparison to settlements under the Stark physician self-referral law. ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will detail ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2
... recognize symptoms and treat returning troops, EAGAN, Minn., ... of the thousands of Minnesota National Guard members throughout,the ... Cross), along with,TriWest Healthcare Alliance and the Minneapolis VA ... The Minnesota National Guard consists of more than ...
... a computer cursor without lifting a finger. Early tests ... as much control as someone using a handheld device. The ... of those same people find it frustrating or impossible to ... Washington provides an alternative using one of the oldest and ...
... announces that it met with the Food and ... a scheduled pre-Investigational New Drug (pre-IND) meeting on ... for Accentia to submit an IND for a ... of Revimmune, the companys potential therapeutic for refractory, ...
... Company Grows Total Number of WellBound Programs ... 9 WellBound, the first,company focused exclusively ... full spectrum of self-care dialysis therapies, today,announced ... dialysis center.,Located is Sacramento, CA, this "Center ...
... CHAPEL HILL, N.C., Oct. 9 Human Resources ... its staff. With HR,involved in some of a ... as relocations or medical services can translate into ... their HR function, Best,Practices, LLC has published a ...
... WASHINGTON, Oct. 9 Girls as young as three,and women ... Eastern,Congo. "Women are dying two types of death," says Christine ... types of,death are the physical and the emotional death. The ... the earth, and the emotional death is where,you no longer ...
Cached Medicine News:Health News:Blue Cross and Partners to Host Combat Stress Conference for Minnesota's Health Care Professionals 2Health News:Blue Cross and Partners to Host Combat Stress Conference for Minnesota's Health Care Professionals 3Health News:Generating 'oohs' and 'aahs': Vocal Joystick uses voice to surf the Internet 2Health News:Generating 'oohs' and 'aahs': Vocal Joystick uses voice to surf the Internet 3Health News:Accentia announces investigational new drug application for Revimmune for refractory MS 2Health News:Accentia announces investigational new drug application for Revimmune for refractory MS 3Health News:WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA 2Health News:WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA 3Health News:HR Under the Microscope: Metrics to Drive Costs Down Across HR Functions 2Health News:Women for Women International Congolese Country Director, Christine Karumba, Speaks Out About the Rape Epidemic in the Democratic Republic of the Congo. 2
The Clinac 6EX accelerator is a cost-effective choice. Configured for the latest treatment techniques, the Clinac 6EX has the tightest mechanical and dosimetric specifications for any single-energy m...
The MULTI-LINK ZETA Coronary Stent System utilizes the same clinically proven implant as the MULTI-LINK PENTA Coronary Stent System, maintaining the benefits of a 17.5% binary restenosis rate....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: